GlassScriptPhysician profile
Gregory R Riva
NPI 1700088630
$12,176.47
in general payments reported to CMS, 2019-2025
33 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,511 · 2020: $847 · 2021: $1,076 · 2022: $1,205 · 2023: $3,394 · 2024: $2,616 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,942 · Travel and Lodging: $2,520 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,942.47 |
| Travel and Lodging | $2,520.25 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,107.42 | 2019-2025 | Aveir, Gallant |
| Novartis Pharmaceuticals Corporation | $1,113.43 | 2019-2025 | |
| Amgen INC. | $1,095.38 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $596.64 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $491.13 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.25 | 2019-2025 | Jardiance |
| Cvrx, INC. | $440.63 | 2022-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $357.87 | 2019-2025 | Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $331.43 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $315.31 | 2019-2025 | |
| Novo Nordisk INC | $280.34 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $264.01 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $185.08 | 2019-2021 | |
| Boston Scientific Corporation | $164.65 | 2020-2024 | Watchman Flx |
| Lexicon Pharmaceuticals, INC. | $159.22 | 2023-2024 | Inpefa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $104.13 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bayer Healthcare Pharmaceuticals INC. | $95.64 | 2021-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $92.45 | 2021-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $80.27 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $45.37 | 2024 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.37 | 2022-2023 | Lifevest |
| Inspire Medical Systems, INC. | $42.94 | 2023 | Inspire |
| Scpharmaceuticals INC. | $38.90 | 2024 | |
| Tactile Systems Technology INC | $33.42 | 2024 | Entre Plus, Flexitouch Plus |
| Gilead Sciences, INC. | $32.59 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.94 | 2025 | Evkeeza |
| Arbor Pharmaceuticals, INC. | $30.80 | 2019-2022 | |
| Cordis US Corp. | $28.56 | 2024 | Mynx Venous Vcd |
| Bridgebio Pharma, INC. | $21.97 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $20.15 | 2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $16.93 | 2019 | |
| Irhythm Technologies, INC. | $16.25 | 2022 | |
| Elutia, INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Riva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.